By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Phosphoproteomics firm Activiomics today announced a technology agreement with biopharmaceutical company UCB to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.
Registering provides access to this and other free content.
Already have an account?Login Now.
Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.
In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.
Scripps Research Institute investigators peer back at the RNA world.
In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.